Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GI Innovation, Inc.
AstraZeneca
Atavistik Bio, Inc
Seagen Inc.
Mayo Clinic
Mayo Clinic
Alterome Therapeutics, Inc.
Bayer
Neonc Technologies, Inc.
ViroMissile, Inc.
Rutgers, The State University of New Jersey
Arcus Biosciences, Inc.
Bristol-Myers Squibb
Kaiser Permanente
AstraZeneca
AstraZeneca
Tizona Therapeutics, Inc
Genentech, Inc.
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
University of Colorado, Denver
MacroGenics
Daiichi Sankyo
Eli Lilly and Company
Adela, Inc
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Medical College of Wisconsin
Innate Pharma
National Institutes of Health Clinical Center (CC)
OncoNano Medicine, Inc.
City of Hope Medical Center
Mayo Clinic